PVCT — Provectus Biopharmaceuticals Income Statement
0.000.00%
- $50.18m
- $53.15m
- $0.56m
Annual income statement for Provectus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.989 | 0.558 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.62 | 4.96 | 4.61 | 4.42 | 3.46 |
Operating Profit | -5.62 | -4.96 | -4.61 | -3.43 | -2.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.92 | -6.68 | -5.54 | -3.55 | -3.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.92 | -6.68 | -5.54 | -3.55 | -3.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.92 | -6.68 | -5.54 | -3.55 | -3.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.92 | -6.68 | -5.54 | -3.55 | -3.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.018 | -0.016 | -0.012 | -0.007 | -0.006 |